Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells ... PD-1 inhibitor Keytruda (pembrolizumab).

Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with olaparib within its marketing authorisation as maintenance treatment of advanced squamous non-small-cell lung ...

(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with ...

Performance of a blood-based test for colorectal cancer screening adjusted to the US census age and sex distribution. Tumour-free ctDNA detection as a decision tool to support organ preservation in ...

Total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for locoregionally advanced low rectal cancer: A phase III randomized controlled trial ...

For information, the company have announced that the trial for pembrolizumab plus lenvatinib in endometrial cancer did not meet its primary endpoint and therefore they will no longer be pursuing a ...

Cervical cancer is a slow-growing cancer that occurs in the cervix, the lower part of the uterus that connects to the vagina.